Acepodia (ROCO:6976) Gross-Profit-to-Asset % : 0.00% (As of Jun. 2023)

View and export this data going back to 2023. Start your Free Trial

What is Acepodia Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Acepodia's annualized Gross Profit for the quarter that ended in Jun. 2023 was NT$0.00 Mil. Acepodia's average Total Assets over the quarter that ended in Jun. 2023 was NT$5,444.64 Mil. Therefore, Acepodia's annualized Gross-Profit-to-Asset % for the quarter that ended in Jun. 2023 was 0.00%.

Acepodia Gross-Profit-to-Asset % Historical Data

The historical data trend for Acepodia's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Acepodia Gross-Profit-to-Asset % Chart

Acepodia Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Gross-Profit-to-Asset %

0.31

Acepodia Semi-Annual Data
	Dec20	Dec21	Jun22	Dec22	Jun23	Dec23
Gross-Profit-to-Asset %	Get a 7-Day Free Trial			-	-	-	-	-

Competitive Comparison of Acepodia's Gross-Profit-to-Asset %

For the Biotechnology subindustry, Acepodia's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Acepodia's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Acepodia's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Acepodia's Gross-Profit-to-Asset % falls into.

Acepodia Gross-Profit-to-Asset % Calculation

Acepodia's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Dec. 2023 )	/	( (Total Assets (A: Dec. 2022 )	+	Total Assets (A: Dec. 2023 ))	/ count )
	=	16.593	/	( (3872.551	+	6818.521)	/ 2 )
	=	16.593	/	5345.536
	=	0.31 %

Acepodia's annualized Gross-Profit-to-Asset % for the quarter that ended in Jun. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Jun. 2023 )	/	( (Total Assets (Q: Dec. 2022 )	+	Total Assets (Q: Jun. 2023 ))	/ count )
	=	0	/	( (3872.551	+	7016.731)	/ 2 )
	=	0	/	5444.641
	=	0.00 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is two times the semi-annual (Jun. 2023) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

Acepodia Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Acepodia's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

Acepodia (ROCO:6976) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Acepodia Inc (ROCO:6976) » Definitions » Gross-Profit-to-Asset %

Comparable Companies

Traded in Other Exchanges

N/A

Address

17th floor-12, Number 99, Section 1, Xintai 5th Road, Xizhi District, New Taipei, TWN, 22175

Website

https://www.acepodia.com

Acepodia Inc is a clinical stage biotechnology company engaged to develop innovative highly effective first-in-class cell therapies by using Antibody-Cell Conjugation platform technology for cancer that are broadly accessible for patients.

Acepodia (ROCO:6976) Headlines

No Headlines